+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Closed Loop Medicine Ltd - Product Pipeline Analysis, 2023 Update

  • PDF Icon

    Company Profile

  • 35 Pages
  • April 2024
  • GlobalData
  • ID: 5952775
Closed Loop Medicine Ltd (Closed Loop Medicine) is a biotechnology company. The company develops drug and digital combination products and personalized regimes. It’s product portfolio includes CLM-HT01 for the treatment of hypertension; CLM-IN01 against sleep disturbances; and CLM-MO03 for chronic pain management. The company’s proprietary technology platform facilitates personalized drug dosing optimization, through the integration of drugs and software with patient-led digital experiences and closed loop models of care. The company evaluates programs to treat diabetes and other metabolic diseases. Closed Loop Medicine works in partnership with Orient Pharma, Innovate UK, NHS Teaching hospitals and other companies. Closed Loop Medicine is headquartered in Cambridge, Middlesex, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Closed Loop Medicine Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Closed Loop Medicine Ltd Company Overview
  • Closed Loop Medicine Ltd Company Snapshot
  • Closed Loop Medicine Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Closed Loop Medicine Ltd - Pipeline Analysis Overview
  • Closed Loop Medicine Ltd - Key Facts
  • Closed Loop Medicine Ltd - Major Products and Services
  • Closed Loop Medicine Ltd Pipeline Products by Development Stage
  • Closed Loop Medicine Ltd Ongoing Clinical Trials by Trial Status
  • Closed Loop Medicine Ltd Pipeline Products Overview
  • CLM-HT01 - Hypertension
  • CLM-HT01 - Hypertension Product Overview
  • CLM-IN02 - Sleep Disturbance In Anxiety
  • CLM-IN02 - Sleep Disturbance In Anxiety Product Overview
  • CLM-MO03 - Metabolic
  • CLM-MO03 - Metabolic Product Overview
  • CLM-OB01
  • CLM-OB01 Product Overview
  • CLM-OP01
  • CLM-OP01 Product Overview
  • CLM-P01 - Chronic Pain Management
  • CLM-P01 - Chronic Pain Management Product Overview
  • Repose Sacral Nerve Stimulator
  • Repose Sacral Nerve Stimulator Product Overview
  • Repose Sacral Nerve Stimulator Clinical Trial
  • Closed Loop Medicine Ltd - Key Competitors
  • Closed Loop Medicine Ltd - Key Employees
  • Closed Loop Medicine Ltd - Locations And Subsidiaries
  • Head Office
  • Recent Developments
  • Closed Loop Medicine Ltd, Recent Developments
  • Feb 08, 2024: Closed Loop Medicine Demonstrates Application of Novel Drug Plus Software Product for Personalized Treatment of Hypertension
  • Jun 20, 2023: Closed Loop Medicine Appoints Kate Woolland as Chief Operating Officer
  • Mar 22, 2022: Closed Loop Medicine announces completion of precision medicine clinical trial for patients with high blood pressure
  • Aug 04, 2021: Closed Loop Medicine announces positive outcome of a key clinical drug study required for regulatory submission of its ‘drug plus digital’ insomnia product CLM-IN01.
  • Jun 03, 2021: Closed Loop Medicine secures UKCA marking and receives CE designation for a Medical Device that will form part of its insomnia product CLM-IN01
  • Nov 18, 2020: Closed Loop Medicine recruits first patient into novel PhIV precision medicine interventional clinical trial for patients with high blood pressure
  • Jul 24, 2020: Closed Loop Medicine secures £250,000 Innovate UK continuity funding
  • Jul 19, 2019: Closed Loop Medicine raises £1.3 million in research grant funding through the InnovateUK Innovation Accelerator, Longwall Ventures and IQ Capital.
  • Jul 19, 2019: Closed Loop Medicine receives major InnovateUK grant award for hypertension clinical programme
  • Oct 19, 2017: Closed Loop Medicine Secures Strategic Partnership With Orient Pharma
  • Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Closed Loop Medicine Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Closed Loop Medicine Ltd Pipeline Products by Equipment Type
  • Closed Loop Medicine Ltd Pipeline Products by Indication
  • Closed Loop Medicine Ltd Ongoing Clinical Trials by Trial Status
  • Closed Loop Medicine Ltd, Key Facts
  • Closed Loop Medicine Ltd, Major Products and Services
  • Closed Loop Medicine Ltd Number of Pipeline Products by Development Stage
  • Closed Loop Medicine Ltd Pipeline Products Summary by Development Stage
  • Closed Loop Medicine Ltd Ongoing Clinical Trials by Trial Status
  • Closed Loop Medicine Ltd Ongoing Clinical Trials Summary
  • CLM-HT01 - Hypertension - Product Status
  • CLM-HT01 - Hypertension - Product Description
  • CLM-IN02 - Sleep Disturbance In Anxiety - Product Status
  • CLM-IN02 - Sleep Disturbance In Anxiety - Product Description
  • CLM-MO03 - Metabolic - Product Status
  • CLM-MO03 - Metabolic - Product Description
  • CLM-OB01 - Product Status
  • CLM-OB01 - Product Description
  • CLM-OP01 - Product Status
  • CLM-OP01 - Product Description
  • CLM-P01 - Chronic Pain Management - Product Status
  • CLM-P01 - Chronic Pain Management - Product Description
  • Repose Sacral Nerve Stimulator - Product Status
  • Repose Sacral Nerve Stimulator - Product Description
  • Repose Sacral Nerve Stimulator - A Prospective Study to Evaluate the Safety and Feasibility of using the Closed Loop Medical Sacral Nerve Stimulation System in the Treatment of Symptoms of Overactive Bladder
  • Closed Loop Medicine Ltd, Key Employees
  • Glossary
List of Figures
  • Closed Loop Medicine Ltd Pipeline Products by Equipment Type
  • Closed Loop Medicine Ltd Pipeline Products by Development Stage
  • Closed Loop Medicine Ltd Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Janssen-Cilag Ltd
  • Amicus Therapeutics UK Ltd
  • Ethypharm UK Ltd